Melphalan

Epidemiology

  • Indications
    • Multiple Myeloma

Pharmacology

  • Alkylating Agent

Adverse Effects

Pulmonary Adverse Effects

  • Acute-Subacute Interstitial Pneumonitis or Interstitial Pulmonary Fibrosis (see Interstitial Lung Disease-Etiology)
    • Epidemiology: only few reported cases of pulmonary toxicity
    • Diagnosis
      • CXR/Chest CT: interstitial infiltrates
    • Clinical: abrupt or insidious onset of dyspnea, cough, fever
    • Treatment/Prognosis: unknown

References

  • Pulmonary fibrosis following therapy with Melphalan for multiple myeloma. J . clin. Path., 1972, 25, 668-673
  • Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. November 2000, Volume 26, Number 10, Pages 1107-1109